RCKT - Rocket Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5755.35M
Enterprise Value 3604.12M
Trailing P/E N/A
Forward P/E 1-6.28
PEG Ratio (5 yr expected) 1-0.76
Price/Sales (ttm)N/A
Price/Book (mrq)3.83
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6-8.65

Trading Information

Stock Price History

Beta (3Y Monthly) 2.72
52-Week Change 3-19.84%
S&P500 52-Week Change 37.40%
52 Week High 325.96
52 Week Low 310.75
50-Day Moving Average 316.75
200-Day Moving Average 316.35

Share Statistics

Avg Vol (3 month) 3307.69k
Avg Vol (10 day) 3212.72k
Shares Outstanding 550.29M
Float 27.61M
% Held by Insiders 15.12%
% Held by Institutions 195.64%
Shares Short (Jun 14, 2019) 46.23M
Short Ratio (Jun 14, 2019) 427.21
Short % of Float (Jun 14, 2019) 420.23%
Short % of Shares Outstanding (Jun 14, 2019) 412.38%
Shares Short (prior month May 15, 2019) 46.26M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 24/1
Last Split Date 3Jan 5, 2018

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-19.09%
Return on Equity (ttm)-45.29%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -69.8M
Net Income Avi to Common (ttm)-78.63M
Diluted EPS (ttm)-1.89
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)196.59M
Total Cash Per Share (mrq)3.91
Total Debt (mrq)45.36M
Total Debt/Equity (mrq)25.61
Current Ratio (mrq)9.70
Book Value Per Share (mrq)3.92

Cash Flow Statement

Operating Cash Flow (ttm)-58.16M
Levered Free Cash Flow (ttm)-23.34M